Gynecological Malignancies (Cervical, Ovarian, Endometrial and Vulval Cancers)
Conditions
Interventions
Test group:Gynecological malignant tumors undergoing systematic lymph node resection during the operation
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients with gynecological malignant tumors (including cervical cancer, ovarian cancer, endometrial cancer and vulvar cancer) who underwent surgical treatment in our hospital; (2) Postoperative pathological diagnosis confirmed as cervical cancer, ovarian cancer, endometrial cancer or vulvar cancer, and lymph node resection was performed during the operation; (3) Complete clinical and pathological data and imaging examination data are available, and enhanced CT examination was conducted within 2 weeks before the operation; (4) The subjects voluntarily participated and signed the informed consent form; (5) According to the judgment of the researchers, there are no absolute surgical contraindications, the patients can tolerate surgical treatment, and they can comply with the trial protocol.
Exclusion criteria
Exclusion criteria: (1) Combined with other malignant tumors; (2) Incomplete clinical data; (3) Active or uncontrolled severe infections; (4) History of immunodeficiency, including HIV positive or having other acquired congenital immune deficiencies; (5) Patients who cannot understand the experimental content and cannot cooperate, or those who refuse to sign the informed consent form; (6) Patients with serious accompanying diseases or other special circumstances that pose a threat to their safety or affect their ability to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymph node metastasis situation;DICOM format file of enhanced CT images of the pelvic cavity;DICOM format file of enhanced MR images of the pelvic cavity;AUC-ROC; | — |
Secondary
| Measure | Time frame |
|---|---|
| pathological pattern;Pathological differentiation;pathological feature;clinical stages;tumor marker;blood routine examination;age;height;weight;Blood coagulation routine test; | — |
Countries
China
Contacts
Public ContactShichao Han
the second affliated hospital of Dalian Medical University
Outcome results
None listed